Austraalia - inglise - Department of Health (Therapeutic Goods Administration)

alembic pharmaceuticals australia pty ltd - oseltamivir phosphate, quantity: 39.411 mg - capsule, hard - excipient ingredients: purified talc; pregelatinised maize starch; sodium stearylfumarate; povidone; croscarmellose sodium; indigo carmine; propylene glycol; butan-1-ol; ethanol; isopropyl alcohol; shellac; strong ammonia solution; titanium dioxide; purified water; iron oxide yellow; iron oxide red; gelatin - oseltamivir phosphate is indicated for the treatment of infections due to influenza a and b viruses in adults and children including full-term neonates. treatment should commence as soon as possible, but no later than 48 hours after the onset of the initial symptoms of infection.,oseltamivir phosphate is indicated for the prevention of influenza in adults and children aged 1 year and older. vaccination is the preferred method of routine prophylaxis against infection with influenza virus.

Austraalia - inglise - Department of Health (Therapeutic Goods Administration)

alembic pharmaceuticals australia pty ltd - oseltamivir phosphate, quantity: 39.411 mg - capsule, hard - excipient ingredients: sodium stearylfumarate; pregelatinised maize starch; croscarmellose sodium; purified talc; povidone; indigo carmine; propylene glycol; butan-1-ol; ethanol; isopropyl alcohol; shellac; strong ammonia solution; titanium dioxide; purified water; iron oxide yellow; iron oxide red; gelatin - oseltamivir phosphate is indicated for the treatment of infections due to influenza a and b viruses in adults and children including full-term neonates. treatment should commence as soon as possible, but no later than 48 hours after the onset of the initial symptoms of infection.,oseltamivir phosphate is indicated for the prevention of influenza in adults and children aged 1 year and older. vaccination is the preferred method of routine prophylaxis against infection with influenza virus.

Ameerika Ühendriigid - inglise - NLM (National Library of Medicine)

quality care products, llc - oseltamivir phosphate (unii: 4a3o49ngez) (oseltamivir acid - unii:k6106lv5q8) - oseltamivir phosphate capsule usp is indicated for the treatment of acute, uncomplicated illness due to influenza a and b infection in patients 2 weeks of age and older who have been symptomatic for no more than 48 hours. oseltamivir phosphate capsule usp is indicated for the prophylaxis of influenza a and b in patients 1 year and older. - oseltamivir phosphate capsule usp is not a substitute for early influenza vaccination on an annual basis as recommended by the centers for disease control and prevention advisory committee on immunization practices. - influenza viruses change over time. emergence of resistance substitutions could decrease drug effectiveness. other factors (for example, changes in viral virulence) might also diminish clinical benefit of antiviral drugs. prescribers should consider available information on influenza drug susceptibility patterns and treatment effects when deciding whether to use oseltamivir phosphate capsule usp [see microbiology (12.4)]. - oseltamivir phosphate capsule usp is

Ameerika Ühendriigid - inglise - NLM (National Library of Medicine)

precision dose, inc. - oseltamivir phosphate (unii: 4a3o49ngez) (oseltamivir acid - unii:k6106lv5q8) - oseltamivir phosphate capsule usp is indicated for the treatment of acute, uncomplicated illness due to influenza a and b infection in patients 2 weeks of age and older who have been symptomatic for no more than 48 hours. oseltamivir phosphate capsule usp is indicated for the prophylaxis of influenza a and b in patients 1 year and older. - oseltamivir phosphate capsule usp is not a substitute for early influenza vaccination on an annual basis as recommended by the centers for disease control and prevention advisory committee on immunization practices. - influenza viruses change over time. emergence of resistance substitutions could decrease drug effectiveness. other factors (for example, changes in viral virulence) might also diminish clinical benefit of antiviral drugs. prescribers should consider available information on influenza drug susceptibility patterns and treatment effects when deciding whether to use oseltamivir phosphate capsule usp [see microbiology (12.4)]. - oseltamivir phosphate capsule usp is

Iisrael - inglise - Ministry of Health

roche pharmaceuticals (israel) ltd - oseltamivir as phosphate - capsules - oseltamivir as phosphate 75 mg - oseltamivir - oseltamivir - treatment of uncomplicated acute illness due to influenza infection in adults patients and patients who weigh more than 40 kg who have been symptomatic for no more than 2 days. - post exposure prevention in adults and patients who weight more the 40 kg following contact with a clinically diagnosed influenza case when influenza virus is circulating in the community. - the appropriate use of tamiflu for prevention of influenza should be determined on a case by case basis by the circumstances and the population requiring protection. in exceptional situations (e.g. in case of a mismatch between the circulating and vaccine virus strains and a pandemic situation) seasonal prevention could be considered in adults patients and patients who weigh more than 40 kg.

Iisrael - inglise - Ministry of Health

roche pharmaceuticals (israel) ltd - oseltamivir as phosphate - capsules - oseltamivir as phosphate 75 mg - oseltamivir - oseltamivir - - treatment of uncomplicated acute illness due to influenza infection in adults patients and patients who weigh more than 40 kg who have been symptomatic for no more than 2 days. - post exposure prevention in adults and patients who weight more the 40 kg following contact with a clinically diagnosed influenza case when influenza virus is circulating in the community. - the appropriate use of tamiflu for prevention of influenza should be determined on a case by case basis by the circumstances and the population requiring protection. in exceptional situations (e.g. in case of a mismatch between the circulating and vaccine virus strains and a pandemic situation) seasonal prevention could be considered in adults patients and patients who weigh more than 40 kg.

Iisrael - inglise - Ministry of Health

roche pharmaceuticals (israel) ltd - oseltamivir as phosphate - capsules - oseltamivir as phosphate 75 mg - oseltamivir - oseltamivir - - treatment of uncomplicated acute illness due to influenza infection in adults patients and patients who weigh more than 40 kg who have been symptomatic for no more than 2 days. - post exposure prevention in adults and patients who weight more the 40 kg following contact with a clinically diagnosed influenza case when influenza virus is circulating in the community. - the appropriate use of tamiflu for prevention of influenza should be determined on a case by case basis by the circumstances and the population requiring protection. in exceptional situations (e.g. in case of a mismatch between the circulating and vaccine virus strains and a pandemic situation) seasonal prevention could be considered in adults patients and patients who weigh more than 40 kg.

Iisrael - inglise - Ministry of Health

roche pharmaceuticals (israel) ltd - oseltamivir as phosphate - capsules - oseltamivir as phosphate 30 mg - oseltamivir - oseltamivir - treatment of influenza : treatment of uncomplicated acute illness due to influenza infection in adults and children 1 year of age or older who have been symptomatic for no more than 2 days. prophylaxis of influenza : post exposure prevention in adults and children 1 year of age or older patients following contact with a clinically diagnosed influenza case when influenza virus is circulating in the community. the appropriate use of tamiflu for prevention of influenza should be determined on a case by case basis by the circumstances and the population requiring protection. in exceptional situations (e.g. in case of a mismatch between the circulating and vaccine virus strains and a pandemic situation) seasonal prevention could be considered in adults and children 1 year of age or older.

Iisrael - inglise - Ministry of Health

roche pharmaceuticals (israel) ltd - oseltamivir as phosphate - capsules - oseltamivir as phosphate 45 mg - oseltamivir - oseltamivir - treatment of influenza : treatment of uncomplicated acute illness due to influenza infection in adults and children 1 year of age or older who have been symptomatic for no more than 2 days. prophylaxis of influenza : post exposure prevention in adults and children 1 year of age or older patients following contact with a clinically diagnosed influenza case when influenza virus is circulating in the community. the appropriate use of tamiflu for prevention of influenza should be determined on a case by case basis by the circumstances and the population requiring protection. in exceptional situations (e.g. in case of a mismatch between the circulating and vaccine virus strains and a pandemic situation) seasonal prevention could be considered in adults and children 1 year of age or older.

Ameerika Ühendriigid - inglise - NLM (National Library of Medicine)

a-s medication solutions - oseltamivir phosphate (unii: 4a3o49ngez) (oseltamivir carboxylate - unii:k6106lv5q8) - oseltamivir phosphate capsules are indicated for the treatment of acute, uncomplicated illness due to influenza a and b infection in patients 2 weeks of age and older who have been symptomatic for no more than 48 hours. oseltamivir phosphate capsules are indicated for the prophylaxis of influenza a and b in patients 1 year and older. - oseltamivir phosphate capsules are not a substitute for early influenza vaccination on an annual basis as recommended by the centers for disease control and prevention advisory committee on immunization practices. - influenza viruses change over time. emergence of resistance substitutions could decrease drug effectiveness. other factors (for example, changes in viral virulence) might also diminish clinical benefit of antiviral drugs. prescribers should consider available information on influenza drug susceptibility patterns and treatment effects when deciding whether to use oseltamivir phosphate capsules [see microbiology (12.4)] . - oseltamivir phosphate capsules are not recom